• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·AOXG
Share

Aoxing Pharmaceutical Company, Inc. Stocks

$ 0Last Updated 27.07.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

$ 266756

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Aoxing Pharmaceutical Company, Inc. is a specialized drug manufacturer primarily operating within the People's Republic of China. The company dedicates itself to the research, development, production, and distribution of pharmaceutical products, with a strong emphasis on narcotics, pain management solutions, and addiction treatments. Its current product portfolio includes Zhongtong'an, a capsule derived from herbal extracts used for relieving oral and dental discomfort; Yiqi Qiangshen Granule, an over-the-counter herbal preparation designed to invigorate qi, strengthen the body, and improve blood flow by clearing meridian blockages; and Tilidine hydrochloride. The latter is an oral synthetic narcotic analgesic tablet, available in 50mg or 100mg doses, prescribed for the alleviation of acute, moderate to severe pain, as well as chronic pain associated with cancer. Aoxing also boasts several promising products in its development pipeline. These include Oxycodone and Acetaminophen tablets and capsules, which have successfully completed clinical trials for both acute and chronic pain management. Another is Buprenorphine/Naloxone, a sublingual combination tablet that has finished Phase II clinical trials as a treatment for opioid dependence. Furthermore, a Tilidine/Naloxone compound capsule is currently undergoing Phase II clinical trials, targeting acute and chronic pain. Initially known as China Aoxing Pharmaceutical Company, Inc., the firm rebranded to Aoxing Pharmaceutical Company, Inc. in March 2010. Its corporate headquarters are situated in Shijiazhuang, China.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.08.2026 04:17

Not a White Knight: How the “Savior” of “AI-Nostradamus” Makes Money by Sensing Trouble

01.08.2026 03:08

Trump Ordered New Strikes Against Iran — WSJ

01.08.2026 02:07

The Nasdaq Composite had its worst July in 20 years due to a plunge in chipmaker stocks

01.08.2026 01:30

Alibaba Supplied 20,000 Nvidia Chips to the Creator of Kimi K3 — Bloomberg

01.08.2026 00:22

"These scars have cost us dearly": "AI Nostradamus" promised not to borrow money anymore

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026